Over the last 4 years, the ACO & Emerging Healthcare Delivery Coalition has continued to grow as a result of the opportunities to hear about innovations in accountable care organizations (ACOs) and to network with a diverse group of people, said Anthony Slonim, MD, DrPH, president and CEO of Renown Health and chair of the ACO Coalition.
Over the last 4 years, the ACO & Emerging Healthcare Delivery Coalition has continued to grow as a result of the opportunities to hear about innovations in accountable care organizations (ACOs) and to network with a diverse group of people, said Anthony Slonim, MD, DrPH, president and CEO of Renown Health and chair of the ACO Coalition.
Transcript
How has the ACO Coalition grown and evolved since its inception?
The ACO Coalition continues to grow. We have more members and more diverse members than we've ever had over the course of our 4 years. And I think that's a testament to what people get when they come to a meeting. They get an opportunity to hear cutting edge work that's innovative. They get to not only understand what people are doing at the research level, but how they apply it in their own ACO. And the networking opportunities are incomparable to anywhere else in the places where you go to get networking.
It's just an amazing place to be and a great opportunity to come together a couple of times a year. And to keep that momentum going, even in between the live meetings.
The ACO Coalition, while it continues to grow in size and diversity, is a place where we like to showcase innovation. So if you have innovative ideas about how you're running your ACO, or how you are advancing the health of your community or the population that you serve, bring it on. We'd love to hear about it and share it with our members.
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More